

PharmaMar sells Zelnova for €33.4 million

- **The Annual General Shareholders' Meeting approved the transaction for which PharmaMar will receive €33,417,000.**
- **This agreement is in line with PharmaMar's strategy to focus on the pharmaceutical sector.**

Madrid, June 28th, 2019.- PharmaMar (MSE:PHM) has announced today the sale of 100% of the shares of its subsidiary Zelnova Zeltia, S.A. to Allentia Invest, S.L. and Safoles, S.A.

The authorization of the sale and purchase agreement was submitted to the Annual General Shareholders' Meeting on June 26th, where it was approved with a sufficient majority, since the purchasing companies are directly and indirectly owned by, among others, Mr. Pedro Fernández Puentes, director of PharmaMar, and persons related to him.

Under the terms of the contract, the buyer has paid the amount of €33,417,000.

Zelnova is a consumer chemicals company that produces and markets insecticides and other products for cleaning, hygiene, disinfection of the home, industry, hotels and restaurants.

This agreement, as with the sale of Xylazel in September 2018, is in line with PharmaMar's strategy that started in 2014, following the reverse merger with Zeltia, to focus on the biopharmaceutical sector.

As reported last January, Alantra Corporate Finance, S.A.U. has advised PharmaMar on this transaction.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.



PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com